Arcturus Therapeutics Holdings Inc. (ARCT)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Total revenue | 28,301 | 29,382 | 41,673 | |
| Research and development, net | 29,579 | 34,893 | 39,134 | |
| General and administrative | 10,338 | 11,315 | 13,276 | |
| Total operating expenses | 39,917 | 46,208 | 52,410 | |
| Loss from operations | -11,616 | -16,826 | -10,737 | |
| Loss from foreign currency | -127 | -21 | -201 | |
| Finance income, net | 2,567 | 2,771 | 3,818 | |
| Net loss before income taxes | -9,176 | -14,076 | -7,120 | |
| Provision (benefit) for income taxes | 4 | - | -217 | |
| Net loss | -9,180 | -14,076 | -6,903 | |
| Comprehensive loss | -9,180 | -14,076 | -6,903 | |
| Basic | -0.34 | -0.52 | -0.26 | |
| Basic | 27,129,000 | 27,107,000 | 27,062,000 | |
| Diluted | -0.34 | -0.52 | -0.26 | |
| Diluted | 27,129,000 | 27,107,000 | 27,062,000 | |